VINCERX PHARMA INC (VINC) Fundamental Analysis & Valuation

NASDAQ:VINC • US92731L3042

0.1 USD
-0.03 (-24.98%)
At close: Apr 22, 2025
0.0639 USD
-0.04 (-36.1%)
After Hours: 4/22/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VINC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

VINC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. While VINC seems to be doing ok healthwise, there are quite some concerns on its profitability. VINC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. VINC Profitability Analysis

1.1 Basic Checks

  • VINC had negative earnings in the past year.
  • In the past year VINC has reported a negative cash flow from operations.
  • In the past 5 years VINC always reported negative net income.
  • In the past 5 years VINC always reported negative operating cash flow.
VINC Yearly Net Income VS EBIT VS OCF VS FCFVINC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • VINC has a Return On Assets of -375.69%. This is amonst the worse of the industry: VINC underperforms 96.12% of its industry peers.
  • VINC has a Return On Equity of -1104.04%. This is amonst the worse of the industry: VINC underperforms 82.89% of its industry peers.
Industry RankSector Rank
ROA -375.69%
ROE -1104.04%
ROIC N/A
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
VINC Yearly ROA, ROE, ROICVINC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • VINC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VINC Yearly Profit, Operating, Gross MarginsVINC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. VINC Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for VINC has been increased compared to 1 year ago.
  • VINC has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for VINC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VINC Yearly Shares OutstandingVINC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
VINC Yearly Total Debt VS Total AssetsVINC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • VINC has an Altman-Z score of -45.83. This is a bad value and indicates that VINC is not financially healthy and even has some risk of bankruptcy.
  • VINC's Altman-Z score of -45.83 is on the low side compared to the rest of the industry. VINC is outperformed by 93.83% of its industry peers.
  • VINC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -45.83
ROIC/WACCN/A
WACCN/A
VINC Yearly LT Debt VS Equity VS FCFVINC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • VINC has a Current Ratio of 1.21. This is a normal value and indicates that VINC is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.21, VINC is not doing good in the industry: 85.19% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.21 indicates that VINC should not have too much problems paying its short term obligations.
  • VINC's Quick ratio of 1.21 is on the low side compared to the rest of the industry. VINC is outperformed by 84.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
VINC Yearly Current Assets VS Current LiabilitesVINC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VINC Growth Analysis

3.1 Past

  • VINC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -968.78%.
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VINC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.65% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VINC Yearly Revenue VS EstimatesVINC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 50M 100M 150M
VINC Yearly EPS VS EstimatesVINC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. VINC Valuation Analysis

4.1 Price/Earnings Ratio

  • VINC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VINC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VINC Price Earnings VS Forward Price EarningsVINC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VINC Per share dataVINC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • VINC's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.4%
EPS Next 3Y25.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VINC Dividend Analysis

5.1 Amount

  • No dividends for VINC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VINC Fundamentals: All Metrics, Ratios and Statistics

VINCERX PHARMA INC

NASDAQ:VINC (4/22/2025, 8:00:01 PM)

After market: 0.0639 -0.04 (-36.1%)

0.1

-0.03 (-24.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-12
Inst Owners10.77%
Inst Owner Change-47.37%
Ins Owners8.37%
Ins Owner Change0%
Market Cap523.00K
Revenue(TTM)N/A
Net Income(TTM)-30.07M
Analysts82.86
Price Target204 (203900%)
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-21.11%
Max EPS beat(2)23.08%
EPS beat(4)2
Avg EPS beat(4)-15.98%
Min EPS beat(4)-141.97%
Max EPS beat(4)76.09%
EPS beat(8)5
Avg EPS beat(8)-4.73%
EPS beat(12)5
Avg EPS beat(12)-7.86%
EPS beat(16)7
Avg EPS beat(16)-3.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3233.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2508.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-20.2
EYN/A
EPS(NY)-12.24
Fwd EYN/A
FCF(TTM)-5
FCFYN/A
OCF(TTM)-5
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -375.69%
ROE -1104.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -45.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.41%
OCF growth 3YN/A
OCF growth 5YN/A

VINCERX PHARMA INC / VINC FAQ

What is the fundamental rating for VINC stock?

ChartMill assigns a fundamental rating of 2 / 10 to VINC.


What is the valuation status for VINC stock?

ChartMill assigns a valuation rating of 1 / 10 to VINCERX PHARMA INC (VINC). This can be considered as Overvalued.


Can you provide the profitability details for VINCERX PHARMA INC?

VINCERX PHARMA INC (VINC) has a profitability rating of 0 / 10.